Mental Disorders Clinical Trial
Official title:
Receptor Occupancy Determined by PET Neuroimaging of [11C]Mirtazapine in Healthy Humans
Recent studies show that 25 – 30% of depressed patients never fully recover, resulting in a
treatment-resistant condition. Thus, depression is a major cause of human suffering. We are
interested in finding new ways of identifying and alleviating treatment-resistant
depression, and we believe that recent advances in brain imaging can contribute to achieving
that goal. In this project, we will use a novel compound ([N-methyl-11C]mirtazapine) that we
invented for examining the neurochemistry of brain receptors involved in antidepressant
actions.
Our compound, [N-methyl-11C]mirtazapine, is closely related to the clinically effective
antidepressant drug mirtazapine (Remeron®). It labels several types of noradrenergic
receptors that have often been implicated in “stress reactions” as well as depressive
disorders. We believe that our compound can identify specific molecular brain dysfunctions
that are causally related to treatment-resistant depression.
The purpose of this study is to determine whether there is a reliable relationship between
the level of mirtazapine in the bloodstream and the occupancy of neuroreceptors by
mirtazapine in the brain. We will apply our standard procedures of PET brain scanning and
region-of-interest data analysis, using healthy volunteers who will receive a daily dose of
mirtazapine (double-blind design with placebo, 7.5 mg or 15 mg daily for 5 days). We believe
that this project could provide a procedure for assessing brain function in
treatment-resistant depression, with the aim of improving the guidelines for successful,
evidence-based treatment of depression.
This project uses a double-blind, placebo-controlled, parallel-group design to determine whether there is a reliable relationship between the level of the antidepressant drug mirtazapine in the bloodstream and the degree of occupancy of neuroreceptors in the brain of healthy human volunteers. The primary data endpoints of the study will be the binding potential of C-11 labelled racemic mirtazapine in the brain under baseline conditions and after 5 days of ingestion of either a placebo tablet or a table containing 7.5 mg or 15 mg of mirtazapine. The degree of receptor occupancy obtained during each experimental condition will be calculated on the basis of the binding potentials in brain regions using data obtained by positron emission tomography (PET scanning). Blood samples will be obtained at the time of PET scanning in order to determine whether there is a reliable correlation between the concentration of mirtazapine in the bloodstream and the degree of receptor occupancy achieved in brain. The study plans to include 24 healthy volunteers with 8 subjects in each of the three groups (placebo, 7.5 mg mirtazapine, and 15 mg mirtazapine). Subjects will be randomized into groups in such a way that each of the three treatments will be used for each of three consecutive subjects that enter the study. This procedure will reduce the possibility that differences in procedures that might occur over time will introduce bias into the results. Radiosynthesis of (C-11)mirtazapine will occur by the authorized and documented procedures currently established at the PET Center of Aarhus University Hospital. ;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Recruiting |
NCT06012149 -
Braining: Implementation of Physical Exercise for Patients in Specialist Psychiatry
|
N/A | |
Recruiting |
NCT03222375 -
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
|
N/A | |
Active, not recruiting |
NCT02836080 -
Integrated Collaborative Care Teams for Youth With Mental Health and/or Addiction Challenges (YouthCan IMPACT)
|
N/A | |
Active, not recruiting |
NCT02907658 -
Efficacy of Internet Use Disorder Prevention
|
N/A | |
Completed |
NCT02710344 -
Using Telehealth to Improve Psychiatric Symptom Management
|
N/A | |
Enrolling by invitation |
NCT02487888 -
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Active, not recruiting |
NCT02761733 -
The Effectiveness of a Decision-Support Tool for Adult Consumers With Mental Health Needs and Their Care Managers
|
N/A | |
Completed |
NCT01947283 -
Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation
|
N/A | |
Completed |
NCT01633138 -
Performance-based Reinforcement to Enhance Cognitive Remediation Therapy
|
N/A | |
Completed |
NCT01690013 -
Life Quality and Health in Patients With Klinefelter Syndrome
|
N/A | |
Completed |
NCT01656707 -
Adaptive Treatment for Adolescent Cannabis Use Disorders
|
N/A | |
Completed |
NCT01415323 -
Agitation in the Acute Psychiatric Department
|
||
Completed |
NCT01701765 -
Outcomes and Discharge of Long-stay Psychiatric Patients
|
N/A | |
Completed |
NCT00375167 -
Efficacy of the Recovery Workbook as a Psychoeducational Tool for Facilitating Recovery
|
N/A | |
Terminated |
NCT00757497 -
Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia
|
Phase 1 | |
Terminated |
NCT03527550 -
Cognitive Control Training for Urgency in a Naturalistic Clinical Setting
|
N/A | |
Withdrawn |
NCT03518996 -
Non-Invasive Brain Stimulation and Delirium
|
N/A |